• Advanced or difficult-to-treat cancers: Solid tumours where standard treatment pathways are limited or unclear.
• Relapsed or refractory disease: Cancer progression or recurrence following first-line therapy.
• Metastatic cancer: Supporting treatment decision-making in complex or late-stage presentations.
• Uncertain therapy direction: Multiple treatment options being considered or limited expected response to standard approaches.
• Rare or aggressive tumour types: Situations where molecular profiling may help identify potential therapeutic targets.
• Monitoring tumour evolution: Re-evaluation of tumour biology during disease progression or after treatment exposure.

Overview

exacta® including drug and natural agents provides a detailed analysis of tumour biology using multi-analyte molecular profiling. It evaluates genetic mutations, gene expression patterns, circulating tumour cells and other biomarkers that may influence tumour behaviour and treatment responsiveness.

By assessing a wide range of molecular targets and cellular pathways, the test may help identify therapies that are more likely to be effective for an individual tumour type. This can be particularly relevant in advanced disease, rare cancers or cases where conventional treatment options have been exhausted.

Results are reviewed alongside tumour subtype, staging, prior treatment history and overall oncological assessment. Integrating molecular findings into this broader clinical context can support more personalised treatment planning and ongoing disease management decisions.

Practical

Specimen

Whole blood

Alternative: FFPE tissue block

Container

• 1x  DCGL tube  
• 1 x EDTA tubes

Volume

20 mL

Patient preparation

Not received blood transfusion at least 10 days prior to collection of sample.

Not chemotherapy/PET-CT/MRI 24 hours before sampling blood

Not positive for HIV / HBV / HCV.